The 1.9 Å crystal structure of alanine racemase from Mycobacterium tuberculosis contains a conserved entryway into the active site

被引:76
作者
LeMagueres, P
Im, H
Ebalunode, J
Strych, U
Benedik, MJ
Briggs, JM
Kohn, H
Krause, KL [1 ]
机构
[1] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA
[2] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA
[3] Univ N Carolina, Sch Pharm, Div Med Chem & Nat Prod, Chapel Hill, NC 27599 USA
[4] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA
关键词
D O I
10.1021/bi0486583
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We report the crystal structure of alanine racemase from Mycobacterium tuberculosis (Alr(Mtb)) at 1.9 Angstrom resolution. In our structure, Alr(Mtb) is found to be a dimer formed by two crystallographically different monomers, each comprising 384 residues. The domain makeup of each monomer is similar to that of Bacillus and Pseudomonas alanine racemases and includes both an alpha/beta-barrel at the N-terminus and a C-terminus primarily made of beta-strands. The hinge angle between these two domains is unique for Alr(Mtb), but the active site geometry is conserved. In Alr(Mtb), the PLP cofactor is covalently bound to the protein via an internal aldimine bond with Lys42. No guest substrate is noted in its active site, although some residual electron density is observed in the enzyme's active site pocket. Analysis of the active site pocket, in the context of other known alanine racemases, allows us to propose the inclusion of conserved residues found at the entrance to the binding pocket as additional targets in ongoing structure-aided drug design efforts. Also, as observed in other alanine racemase structures, PLP adopts a conformation that significantly distorts the planarity of the extended conjugated system between the PLP ring and the internal aldimine bond.
引用
收藏
页码:1471 / 1481
页数:11
相关论文
共 50 条
  • [1] Bloom Barry R., 1994, TUBERCULOSIS PATHOGE
  • [2] Bruinstejn A., 1985, SEMINARA MEZHDUNAR U, P326
  • [3] Chobanian AV., 2003, HYPERTENSION, V42, P1206, DOI [10.1161/01.HYP.0000107251.49515.c2, DOI 10.1161/01.HYP.0000107251.49515.C2]
  • [4] Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
    Cole, ST
    Brosch, R
    Parkhill, J
    Garnier, T
    Churcher, C
    Harris, D
    Gordon, SV
    Eiglmeier, K
    Gas, S
    Barry, CE
    Tekaia, F
    Badcock, K
    Basham, D
    Brown, D
    Chillingworth, T
    Connor, R
    Davies, R
    Devlin, K
    Feltwell, T
    Gentles, S
    Hamlin, N
    Holroyd, S
    Hornby, T
    Jagels, K
    Krogh, A
    McLean, J
    Moule, S
    Murphy, L
    Oliver, K
    Osborne, J
    Quail, MA
    Rajandream, MA
    Rogers, J
    Rutter, S
    Seeger, K
    Skelton, J
    Squares, R
    Squares, S
    Sulston, JE
    Taylor, K
    Whitehead, S
    Barrell, BG
    [J]. NATURE, 1998, 393 (6685) : 537 - +
  • [5] INHIBITION OF ALANINE RACEMASE BY ALANINE PHOSPHONATE - DETECTION OF AN IMINE LINKAGE TO PYRIDOXAL 5'-PHOSPHATE IN THE ENZYME-INHIBITOR COMPLEX BY SOLID-STATE N-15 NUCLEAR MAGNETIC-RESONANCE
    COPIE, V
    FARACI, WS
    WALSH, CT
    GRIFFIN, RG
    [J]. BIOCHEMISTRY, 1988, 27 (14) : 4966 - 4970
  • [6] Prospects for worldwide tuberculosis control under the WHO DOTS strategy
    Dye, C
    Garnett, GP
    Sleeman, A
    Williams, BG
    [J]. LANCET, 1998, 352 (9144) : 1886 - 1891
  • [7] A side reaction of alanine racemase: Transamination of cycloserine
    Fenn, TD
    Stamper, GF
    Morollo, AA
    Ringe, D
    [J]. BIOCHEMISTRY, 2003, 42 (19) : 5775 - 5783
  • [8] TREATMENT OF 171 PATIENTS WITH PULMONARY TUBERCULOSIS RESISTANT TO ISONIAZID AND RIFAMPIN
    GOBLE, M
    ISEMAN, MD
    MADSEN, LA
    WAITE, D
    ACKERSON, L
    HORSBURGH, CR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) : 527 - 532
  • [9] Goodsell DS, 1996, J MOL RECOGNIT, V9, P1, DOI 10.1002/(SICI)1099-1352(199601)9:1<1::AID-JMR241>3.0.CO
  • [10] 2-6